ER
ERFSF.US Eurofins Scientific SE
- Market cap
- USD 16.6B
- P/E
- 28.5x
- P/B
- 3.25x
- ROE
- 33.4%
- Dividend yield
- 0.87%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is ERFSF.US undervalued?
Graham numberERFSF.US trades 102.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Eurofins Scientific SE fundamental analysis
No fundamental analysis for Eurofins Scientific SE yet.
Eurofins Scientific SE stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Eurofins Scientific SE
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. It provides services, such as agroscience, including biological assessment, consumer and human, environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, including sustainability, audit, certification, quality inspection, QA-QC programme, and food and dietary supplement labelling services; biopharma,…
Full company profileEurofins Scientific SE financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Eurofins Scientific SE annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.54B | 2.97B | 3.78B | 4.56B | 5.44B | 6.72B | 6.71B | 6.51B | 6.95B | 7.29B | 14.8B |
| Gross Profit | 1.64B | 1.91B | 2.43B | 3.06B | 3.69B | 4.57B | 1.51B | 1.37B | 4.71B | 4.97B | 1.99B |
| Operating Income | 282M | 287M | 338M | 422M | 1.29B | 1.26B | 783M | 1.24B | 726M | 818M | 1.99B |
| EBITDA | 453M | 481M | 579M | 765M | 1.33B | 1.65B | 1.51B | 1.22B | 1.56B | 1.53B | 3.18B |
| Net Income | 174M | 217M | 224M | 195M | 539M | 783M | 610M | 310M | 406M | 475M | 1.21B |
| EPS | 1.03 | 1.20 | 1.22 | 1.05 | 2.75 | 3.90 | 3.07 | 1.57 | 2.09 | 2.54 | 6.57 |
| Balance Sheet | |||||||||||
| Total Assets | 4.13B | 5.83B | 7.21B | 7.82B | 8.58B | 9.33B | 10.1B | 10.9B | 10.9B | 11.0B | 11.1B |
| Total Liabilities | 2.37B | 3.35B | 4.48B | 4.93B | 4.86B | 4.66B | 5.23B | 5.75B | 5.50B | 7.40B | 7.44B |
| Shareholders' Equity | 1.63B | 2.44B | 2.67B | 2.84B | 3.69B | 4.65B | 4.78B | 5.08B | 5.34B | 3.54B | 3.61B |
| Cash & Short-term Investments | 826M | 820M | 506M | 297M | 912M | 515M | 487M | 1.23B | 614M | 791M | 617M |
| Total Debt | 1.38B | 2.22B | 3.16B | 3.54B | 3.15B | 2.75B | 3.33B | 3.93B | 3.61B | 4.43B | 5.46B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 372M | 405M | 544M | 678M | 1.22B | 1.51B | 1.14B | 1.02B | 1.32B | 1.29B | 2.30B |
| Capital Expenditure | 200M | 246M | 364M | 425M | 356M | 520M | 660M | 550M | 528M | 760M | 763M |
| Free Cash Flow | 172M | 159M | 179M | 253M | 868M | 990M | 476M | 468M | 791M | 535M | 1.53B |
| Ratios | |||||||||||
| ROE | 10.7% | 8.9% | 8.4% | 6.9% | 14.6% | 16.8% | 12.8% | 6.1% | 7.6% | 13.4% | 33.4% |
| ROA | 4.2% | 3.7% | 3.1% | 2.5% | 6.3% | 8.4% | 6.1% | 2.8% | 3.7% | 4.3% | 10.9% |
| Net Profit Margin | 6.9% | 7.3% | 5.9% | 4.3% | 9.9% | 11.6% | 9.1% | 4.8% | 5.8% | 6.5% | 8.2% |
| Debt to Equity | 0.85x | 0.91x | 1.18x | 1.25x | 0.85x | 0.59x | 0.70x | 0.77x | 0.68x | 1.25x | 1.51x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Eurofins Scientific SE dividends
- Dividend yield
- 0.87%
- Forward dividend
- 0.84 USD
- Payout ratio
- 23.2%
- Ex-dividend date
- Apr 28, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 110M | 0.59 | 23.2% |
| 2024 | EUR 95.6M | 0.49 | 23.5% |
| 2023 | EUR 234M | 1.18 | 75.4% |
| 2022 | EUR 193M | 0.97 | 31.5% |
| 2021 | EUR 130M | 0.65 | 16.7% |
| 2020 | EUR 500K | 0.00 | 0.1% |
| 2019 | EUR 51.4M | 0.28 | 26.3% |
| 2018 | EUR 42.6M | 0.23 | 19.0% |
| 2017 | EUR 34.9M | 0.19 | 16.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 10:1 on Nov 19, 2020.
Who owns Eurofins Scientific SE
- Insiders 36.55%
- Institutions 35.63%
- Public & others 27.82%
- Shares outstanding 171M
- Free float 108M
Eurofins Scientific SE company profile
- Company name
- Eurofins Scientific SE
- Ticker
- ERFSF.US
- ISIN
- FR0014000MR3
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 65,000
- Fiscal year end
- December
- Address
- 23 Val Fleuri, Luxembourg, Luxembourg, 1526
- Phone
- 352 26 18 53 20
- Website
- eurofins.com
About Eurofins Scientific SE
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. It provides services, such as agroscience, including biological assessment, consumer and human, environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, including sustainability, audit, certification, quality inspection, QA-QC programme, and food and dietary supplement labelling services; biopharma, and clinical diagnostics. The company also offers consumer product testing, which include sustainability, testing, certifications and approvals, expert services and regulatory, inspections, audits, consumer research and sensory evaluation, and training courses; cosmetics and personal care; and electrical and electronics laboratories services. In addition, it provides environment testing, including maritime, water, air, soil, building material, pollution, waste, fuel/oil, microplastics, and radioactivity testing; and food and feed testing that include allergen, audit and certification, authenticity, carbohydrates, consulting, dioxins and POPs, food irradiation, GMO, heavy metal, melamine, microbiology, molecular biology, mycotoxin, nutritional analyses, organic contaminants, pesticide, veterinary drug, vitamin, and residual DNA testing. Further, the company provides forensic, genomic, maritime, materials and engineering, REACH, and sensory and consumer services, as well as in vitro diagnostics and PSS insourcing solutions. The company was founded in 1987 and is headquartered in Luxembourg, Luxembourg.
Eurofins Scientific SE management
10- Dr. Gilles G. Martin Ph.D.Chairman of the Board & CEO · born 1963
- Ms. Valerie HanoteExecutive Director · born 1966
- Mr. Laurent LebrasGroup Administration & CFO
- Mr. Gonzalo MeleGroup Chief Information Officer
- Mr. Andrew SwiftHead of Investor Relations
- Mr. David W. BryantSenior VP of Strategic Business Development North America
- Mr. Gabriel JuliaSenior VP of Clinical Diagnostics Europe
- Dr. Timothy S. OostdykExecutive VP of BioPharma, Genomics & Agrosciences Services North America
- Mr. Joachim ReicheltSenior Vice President of Food & Feed Testing Europe
- Ms. Yvoine RemySenior Vice President of Environment Testing Europe